Evaluating the impact of Xpert^® MTB/RIF on mortality from TB: are we asking the right questions?

Public Health Action. 2022 Jun 21;12(2):53-54. doi: 10.5588/pha.22.0021.

Authors

K Chani^{1

2}, M P Sekadde³, R A Dlodlo⁴, S M Graham^{2

5}

Affiliations

¹ Australian National University, Canberra ACT, Australia.
² Burnet Institute, Melbourne, VIC, Australia.
³ National Tuberculosis and Leprosy Programme, Kampala, Uganda.
⁴ International Union Against Tuberculosis and Lung Disease (The Union), Bulawayo, Zimbabwe.
⁵ University of Melbourne Department of Paediatrics, Royal Children's Hospital, Melbourne, VIC, Australia.

No abstract available

Publication types

Editorial